Quantifying the Impact of Public Perceptions on Vaccine Acceptance Using Behavioral Economics.
Adult
Aged
Aged, 80 and over
COVID-19
/ epidemiology
COVID-19 Vaccines
/ economics
Cross-Sectional Studies
Economics, Behavioral
/ statistics & numerical data
Female
Humans
Male
Middle Aged
Pandemics
/ prevention & control
Patient Acceptance of Health Care
/ psychology
Perception
SARS-CoV-2
Surveys and Questionnaires
United States
/ epidemiology
Vaccination
/ economics
COVID-19
behavioral economics
demand
vaccination
vaccine
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
09
2020
accepted:
13
11
2020
entrez:
21
12
2020
pubmed:
22
12
2020
medline:
2
1
2021
Statut:
epublish
Résumé
This study was conducted to evaluate the impact of public perceptions of vaccine safety and efficacy on intent to seek COVID-19 vaccination using hypothetical vaccine acceptance scenarios. The behavioral economic methodology could be used to inform future public health vaccination campaigns designed to influence public perceptions and improve public acceptance of the vaccine. In June 2020, 534 respondents completed online validated behavioral economic procedures adapted to evaluate COVID-19 vaccine demand in relation to a hypothetical development process and efficacy. An exponential demand function was used to describe the proportion of participants accepting the vaccine at each efficacy. Linear mixed effect models evaluated development process and individual characteristic effects on minimum required vaccine efficacy required for vaccine acceptance. The rapid development process scenario increased the rate of decline in acceptance with reductions in efficacy. At 50% efficacy, 68.8% of respondents would seek the standard vaccine, and 58.8% would seek the rapid developed vaccine. Rapid vaccine development increased the minimum required efficacy for vaccine acceptance by over 9 percentage points, γ = 9.36,
Identifiants
pubmed: 33344407
doi: 10.3389/fpubh.2020.608852
pmc: PMC7744757
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
608852Subventions
Organisme : NIDA NIH HHS
ID : T32 DA007209
Pays : United States
Informations de copyright
Copyright © 2020 Hursh, Strickland, Schwartz and Reed.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Emerg Infect Dis. 2020 Jul;26(7):1470-1477
pubmed: 32255761
Psychol Rev. 2008 Jan;115(1):186-98
pubmed: 18211190
Exp Clin Psychopharmacol. 2019 Feb;27(1):1-18
pubmed: 30489114
Front Psychol. 2013 May 21;4:279
pubmed: 23734136
JAMA. 2020 Jun 23;323(24):2460-2461
pubmed: 32453392
Nicotine Tob Res. 2019 May 21;21(6):784-791
pubmed: 29547973
Immunity. 2020 May 19;52(5):737-741
pubmed: 32433946
Science. 1974 Sep 27;185(4157):1124-31
pubmed: 17835457
Annu Rev Clin Psychol. 2016;12:53-81
pubmed: 26772208
Behav Processes. 2015 Apr;113:187-91
pubmed: 25712039
Vaccine. 2011 Sep 2;29(38):6472-84
pubmed: 21756960
Addiction. 2020 Mar;115(3):393-406
pubmed: 31454109
JAMA. 2020 Jul 28;324(4):337-338
pubmed: 32597963
Hum Vaccin Immunother. 2020 Sep 1;16(9):2204-2214
pubmed: 32730103
JAMA. 2020 Jun 23;323(24):2458-2459
pubmed: 32421155
J Exp Anal Behav. 2013 Jan;99(1):98-124
pubmed: 23344991
PLoS One. 2013 Dec 11;8(12):e82131
pubmed: 24349200
Prev Med. 2019 Nov;128:105789
pubmed: 31400376
Alcohol Clin Exp Res. 2012 Apr;36(4):716-24
pubmed: 22017303
J Exp Anal Behav. 1980 Sep;34(2):219-38
pubmed: 16812188
J Exp Anal Behav. 1984 Nov;42(3):435-52
pubmed: 16812401